Bristol-Myers Squibb Company

Bristol-Myers Squibb is a US biopharmaceutical company headquartered in Princeton, New Jersey. Its shares trade on the New York Stock Exchange under the ticker BMY, and the company is included in the S&P 500 index. The current structure emerged in 1989 from the merger of Squibb, founded in 1858, and Bristol-Myers, founded in 1887.

The company works in cancer (oncology), hematology, immune diseases, cardiovascular diseases and neuroscience. Its well-known products include the cancer immunotherapy Opdivo, the anticoagulant Eliquis marketed together with Pfizer, the cell therapy Breyanzi and the heart muscle disease medicine Camzyos. The company widened its pipeline by acquiring Celgene in 2019 and Karuna Therapeutics in 2024; Cobenfy, which came from Karuna, is used in the treatment of schizophrenia.

Those following Bristol-Myers Squibb stock typically watch patent expiry dates and generic competition, new drug approvals, clinical trial results and drug pricing rules in the United States. On the BMY page at Lzzo.com, the share price is shown in US dollars, and the page includes a historical price chart and technical indicators.